Metoprololsuccinat Stada

Metoprolol Tartrate, the active ingredient in Metoprololsuccinat Stada, is a beta‑blocker presented as oral tablets for oral use. It is employed to lower blood pressure, relieve angina and improve outcomes in heart failure patients. GNH USA supplies Metoprololsuccinat Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Tartrate acts on the cardiovascular system to control blood pressure and reduce cardiac workload. - Hypertension: lowers systolic and diastolic pressure, decreasing long‑term cardiovascular risk. - Angina pectoris: reduces myocardial oxygen demand, alleviating chest pain episodes. - Post‑myocardial infarction: improves survival by limiting arrhythmias and remodeling. - Chronic heart failure: enhances left‑ventricular function and reduces hospitalisation rates.

Metoprolol Tartrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities - Gastrointestinal upset (nausea, abdominal discomfort) - Headache

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in asthmatic patients - Acute decompensated heart failure - Allergic reactions (rash, angioedema) - Depression or mood changes

Before initiating therapy, clinicians should consider several safety aspects. - Monitor heart rate: ensure rate does not fall below recommended limits. - Assess blood pressure: watch for excessive hypotension after dose changes. - Use caution in asthma or chronic obstructive pulmonary disease: β1‑selectivity may not fully prevent bronchospasm. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension or tachycardia. - Adjust dose in renal impairment: reduced clearance may increase exposure. - Store at room temperature: keep in the original pack, protect from moisture.

Metoprolol Tartrate can interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid): - Other β‑blockers or non‑selective β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): potentiate heart‑rate slowing and AV‑block. - Antiarrhythmic agents (class I): increase risk of conduction disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: combined effect on blood pressure and electrolytes requires monitoring. - Antidiabetic agents (insulin, sulfonylureas): may mask hypoglycaemia symptoms.